We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Blood Tests Can Detect Inflammatory Bowel Diseases Years before Diagnosis

By LabMedica International staff writers
Posted on 08 Nov 2023
Print article
Image: The researchers looked at several clinical tests up to 10 years before inflammatory bowel disease diagnosis (Photo courtesy of M. Cell Reports Medicine)
Image: The researchers looked at several clinical tests up to 10 years before inflammatory bowel disease diagnosis (Photo courtesy of M. Cell Reports Medicine)

Inflammatory bowel diseases (IBD), which include Crohn's disease and ulcerative colitis, are chronic conditions that lead to ongoing inflammation in the digestive tract. This results in discomfort and symptoms such as stomach pain and persistent diarrhea. Recognizing and managing these conditions early is crucial for better patient outcomes. Past assumptions held that most patients experienced symptoms approximately one year prior to being diagnosed. However, the presence of significant damage to the bowels at the time of diagnosis indicated that these diseases might have been developing for a much more extended period. Now, new research has revealed that certain signs of Crohn’s disease can be identified through blood tests up to eight years before its diagnosis, and signs of ulcerative colitis can be detected up to three years prior.

This research, carried out by investigators at the Francis Crick Institute (London, UK) and Aalborg University (Copenhagen, Denmark), highlights that the onset of inflammatory bowel diseases occurs well before symptoms manifest. This discovery opens the possibility for healthcare providers to intervene preemptively or to start treatment at an earlier, potentially more effective stage. The researchers reached their findings by reviewing ten years of blood test results leading up to an IBD diagnosis. They noted variations in specific blood minerals, cell counts, and inflammation indicators, including fecal calprotectin—a marker released during bowel inflammation and currently used to decide if a person with gastrointestinal complaints should undergo more detailed examinations. These variations became noticeable up to eight years before Crohn's disease was diagnosed and three years before ulcerative colitis was diagnosed.

What's particularly noteworthy is that many of these changes were minor and fell within what would be considered normal ranges in standard blood tests, meaning they wouldn't typically trigger alarms for further action. It took a comprehensive analysis of a large volume of data to spot these subtle changes among various indicators. The researchers aim to delve further, exploring whether initiating treatment or preventive measures before symptoms appear could be beneficial, and examining whether these research insights could help predict who might develop IBD in the future.

“Our research shows that the bowel damage we’re seeing at the point of diagnosis is just the tip of the iceberg. So many changes are subtly taking place in the body before the disease takes hold,” said James Lee, Group Leader of the Genetic Mechanisms of Disease Laboratory at the Crick. “This has huge implications for prevention as it highlights that there’s a window of opportunity for treatment.”

“Our findings are novel and go hand-in-hand with emerging evidence that chronic inflammatory bowel diseases likely have their onset years prior to diagnosis,” added Tine Jess, Director at the Center for Molecular Prediction of Inflammatory Bowel Disease, PREDICT, at Aalborg University.

Related Links:
Francis Crick Institute
Aalborg University

Gold Member
Troponin T QC
Troponin T Quality Control
New
Gold Member
Strep Pneumoniae Rapid Test
Strep Pneumoniae (6503 – 6573)
New
Syphilis Infection Test
IMPACT RPR
New
Hematology Analyzer
BH-6180

Print article

Channels

Microbiology

view channel
Image: The QIAstat-Dx mini gastrointestinal panel has secured U.S. clearance to support year-round outpatient care (Photo courtesy of QIAGEN)

Syndromic Panel Provides Fast Answers for Outpatient Diagnosis of Gastrointestinal Conditions

Acute infectious gastroenteritis is a major cause of outpatient visits and hospitalizations in the U.S., with over 179 million cases estimated annually. Now, a new gastrointestinal panel designed to provide... Read more

Pathology

view channel
Image: The AI tool can search through data and histology images for much more precise information on cancer treatment effectiveness (Photo courtesy of Shutterstock)

AI Tool Analyzes 30K Data Points Per Medical Imaging Pixel in Cancer Search

A new artificial intelligence (AI)-powered tool can detect cell-level characteristics of cancer by analyzing data from very small tissue samples, some as tiny as 400 square micrometers, equivalent to the... Read more

Technology

view channel
Image: Human tear film protein sampling methods (Photo courtesy of Clinical Proteomics. 2024 Mar 13;21:23. doi: 10.1186/s12014-024-09475-8)

New Lens Method Analyzes Tears for Early Disease Detection

Bodily fluids, including tears and saliva, carry proteins that are released from different parts of the body. The presence of specific proteins in these biofluids can be a sign of health issues.... Read more

Industry

view channel
Image: The game-changing immunoassay diagnostics platform delivers results from whole blood sample in 10 minutes (Photo courtesy of SpinChip)

bioMérieux Acquires Norwegian Immunoassay Start-Up SpinChip Diagnostics

bioMérieux (Marcy l’Étoile, France) has agreed to acquire SpinChip Diagnostics (Oslo, Norway), the developer of a game-changing immunoassay diagnostics platform. The small benchtop analyzer is well adapted... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.